IL27 and experimental autoimmune encephalomyelitis: On the other end of the spectrum, IL-27 agonism has been explored for its therapeutic use in inflammatory autoimmune dysregulation such as experimental autoimmune encephalomyelitis (Fitzgerald et al., 2013) and colitis (Hanson et al., 2014).